可溶性CD44标准型、CD44变异体5和CD44变异体6及其与头颈癌分期的关系。

Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.

作者信息

Kawano Toshirou, Yanoma Shunsuke, Nakamura Yoshiyasu, Ozeki Akemi, Kokatsu Toshiyuki, Kubota Akira, Furukawa Madoka, Tsukuda Mamoru

机构信息

Department of Otorhinolaryngology, Hiratsuka Kyousai Hospital, Oiwake Hiratsuka, Kanagawa, Japan.

出版信息

Acta Otolaryngol. 2005 Apr;125(4):392-7. doi: 10.1080/00016480510026971.

DOI:10.1080/00016480510026971

PMID:15823810

Abstract

CONCLUSION

The possible roles of CD44st, CD44v5 and CD44v6 in the prognosis of head and neck cancer deserve further elucidation and evaluation with long-term patient follow-up.

OBJECTIVE

Standard CD44 (CD44st), CD44 variant 5 (CD44v5) and CD44 variant 6 (CD44v6) are expressed in human malignant cells and tissues. The mechanism of their expression remains unclear, but has been reported to be associated with the progression and metastasis of malignancies. Recently, it has frequently been reported that the prognosis of head and neck cancer is associated with expression of the cell adhesion molecule CD44.

MATERIAL AND METHODS

We investigated correlations between the soluble adhesion molecule CD44 and clinicopathologic variables, for example, age, sex, histologic grade, tumor size, lymph node status, distant metastasis and TNM stage. The pre- and post-treatment serum levels of CD44st, CD44v5 and CD44v6 were determined by means of ELISAs in 81 patients with head and neck cancer and 20 healthy volunteers (controls).

RESULTS

In the cancer patients, the pre-treatment median serum levels of CD44st, CD44v5 and CD44v6 were 327 +/- 134, 312 +/- 118 and 211 +/ 110 ng/ml, respectively. The corresponding post-treatment levels were 185 +/- 103, 177 +/- 90 and 110 +/- 65 ng/ml. In the healthy volunteers, the median serum levels of CD44st, CD44v5 and CD44v6 were 133 +/- 40, 142 +/- 39 and 86 +/- 22 ng/ml, respectively. In the cancer patients, there was no significant correlation between the serum levels of CD44st, CD44v5 and CD44v6 and the clinicopathological variables. The pre-treatment serum levels of CD44st, CD44v5 and CD44v6 were closely associated with TNM stage (p = 0.0017, 0.0005 and 0.0046, respectively). The median pre-treatment serum levels of CD44st, CD44v5 and CD44v6 were significantly higher than those in the control group (p = 0.0002, 0.0065 and 0.0038, respectively). The median post- treatment serum levels of CD44st, CD44v5 and CD44v6 were significantly lower than the pre-treatment levels (p = 0.0003, 0.0027 and 0.0034, respectively).

摘要

结论

CD44标准型（CD44st）、CD44变异体5（CD44v5）和CD44变异体6（CD44v6）在头颈部癌预后中的可能作用值得通过对患者进行长期随访作进一步阐明和评估。

目的

标准CD44（CD44st）、CD44变异体5（CD44v5）和CD44变异体6（CD44v6）在人类恶性细胞和组织中表达。其表达机制尚不清楚，但据报道与恶性肿瘤的进展和转移有关。最近，经常有报道称头颈部癌的预后与细胞黏附分子CD44的表达有关。

材料与方法

我们研究了可溶性黏附分子CD44与临床病理变量之间的相关性，例如年龄、性别、组织学分级、肿瘤大小、淋巴结状态、远处转移和TNM分期。采用酶联免疫吸附测定法（ELISA）测定了81名头颈部癌患者和20名健康志愿者（对照组）治疗前后血清中CD44st、CD44v5和CD44v6的水平。

结果

在癌症患者中，治疗前CD44st、CD44v5和CD44v6的血清中位水平分别为327±134、312±118和211±110 ng/ml。相应的治疗后水平分别为185±103、177±90和110±65 ng/ml。在健康志愿者中，CD44st、CD44v5和CD44v6的血清中位水平分别为133±40、142±39和86±22 ng/ml。在癌症患者中，CD44st、CD44v5和CD44v6的血清水平与临床病理变量之间无显著相关性。CD44st、CD44v5和CD44v6的治疗前血清水平与TNM分期密切相关（p值分别为0.0017、0.0005和0.0046）。CD44st、CD44v5和CD44v6的治疗前血清中位水平显著高于对照组（p值分别为0.0002, 0.0065和0.0038）。CD44st、CD44v5和CD44v6的治疗后血清中位水平显著低于治疗前水平（p值分别为0.0003、0.0027和0.0034）。